Kayne Anderson Rudnick Investment Management
AZN icon

Kayne Anderson Rudnick Investment Management’s AstraZeneca AZN Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Buy
21,789
+7,373
+51% +$1.39M 0.01% 286
2026
Q1 		$2.84M Buy
14,416
+2,136
+17% +$412K 0.01% 298
2025
Q4 		$2.26M Buy
12,280
+643
+6% +$113K 0.01% 320
2025
Q3 		$1.79M Buy
11,637
+699
+6% +$106K ﹤0.01% 338
2025
Q2 		$1.53M Buy
10,938
+9,790
+853% +$1.37M ﹤0.01% 342
2025
Q1 		$169K Buy
1,148
+951
+483% +$138K ﹤0.01% 496
2024
Q4 		$25.8K Hold
197
– – ﹤0.01% 609
2024
Q3 		$30.6K Buy
197
+44
+29% +$7.1K ﹤0.01% 588
2024
Q2 		$23.9K Buy
153
+15
+11% +$2.26K ﹤0.01% 578
2024
Q1 		$18.6K Hold
138
– – ﹤0.01% 595
2023
Q4 		$18.5K Buy
138
+77
+126% +$10K ﹤0.01% 582
2023
Q3 		$8.19K Hold
61
– – ﹤0.01% 594
2023
Q2 		$8.66K Buy
+61
New +$8.97K ﹤0.01% 586
2022
Q2 		– Sell
-104
Closed -$14K – 607
2022
Q1 		$14K Buy
104
+76
+271% +$9.11K ﹤0.01% 516
2021
Q4 		$3K Buy
+28
New +$3.29K ﹤0.01% 569
2021
Q1 		– Sell
-57
Closed -$6K – 575
2020
Q4 		$6K Buy
+57
New +$6.04K ﹤0.01% 491
2020
Q2 		– Sell
-310
Closed -$28K – 545
2020
Q1 		$28K Sell
310
-35,863
-99% -$3.38M ﹤0.01% 415
2019
Q4 		$3.61M Sell
36,173
-31,596
-47% -$2.97M 0.02% 239
2019
Q3 		$6.04M Buy
67,769
+1,842
+3% +$160K 0.03% 209
2019
Q2 		$5.44M Buy
65,927
+358
+0.5% +$28.1K 0.03% 214
2019
Q1 		$5.3M Buy
65,569
+428
+0.7% +$33.7K 0.03% 202
2018
Q4 		$4.95M Sell
65,141
-58,886
-47% -$4.6M 0.03% 203
2018
Q3 		$9.81M Sell
124,027
-54,336
-30% -$4.11M 0.06% 173
2018
Q2 		$12.5M Sell
178,363
-8,947
-5% -$644K 0.08% 158
2018
Q1 		$13.1M Sell
187,310
-18,958
-9% -$1.31M 0.1% 152
2017
Q4 		$14.3M Buy
206,268
+1,645
+0.8% +$111K 0.12% 151
2017
Q3 		$13.9M Sell
204,623
-721
-0.4% -$45.5K 0.13% 152
2017
Q2 		$14M Sell
205,344
-5,281
-3% -$345K 0.14% 153
2017
Q1 		$13.1M Buy
210,625
+34,847
+20% +$2.03M 0.14% 153
2016
Q4 		$9.6M Sell
175,778
-11,873
-6% -$674K 0.11% 171
2016
Q3 		$12.3M Buy
187,651
+163,572
+679% +$10.7M 0.15% 165
2016
Q2 		$1.45M Buy
24,079
+786
+3% +$45.7K 0.02% 258
2016
Q1 		$1.31M Sell
23,293
-455
-2% -$27.3K 0.02% 253
2015
Q4 		$1.61M Sell
23,748
-1,764
-7% -$116K 0.03% 238
2015
Q3 		$1.62M Buy
25,512
+4,196
+20% +$276K 0.03% 224
2015
Q2 		$1.36M Buy
21,316
+12,854
+152% +$880K 0.02% 234
2015
Q1 		$579K Buy
8,462
+1,585
+23% +$110K 0.01% 265
2014
Q4 		$484K Sell
6,877
-9,946
-59% -$712K 0.01% 280
2014
Q3 		$1.2M Buy
16,823
+5,827
+53% +$427K 0.02% 236
2014
Q2 		$817K Sell
10,996
-1,457
-12% -$105K 0.01% 257
2014
Q1 		$808K Buy
12,453
+4,131
+50% +$267K 0.01% 243
2013
Q4 		$494K Buy
8,322
+4,030
+94% +$219K 0.01% 251
2013
Q3 		$223K Buy
+4,292
New +$216K ﹤0.01% 268

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's AZN Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management increased its AstraZeneca (AZN) stake by 51% in Q2 2026, buying an estimated $1.39M and bringing the position to 21,789 shares worth $4.13M. The position accounts for 0.01% of the portfolio, ranked #286.

Kayne Anderson Rudnick Investment Management first reported a position in AZN in Q3 2013 and has held it in 43 quarters since. The position peaked at $14.3M in Q4 2017. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Kayne Anderson Rudnick Investment Management held 21,789 shares of AstraZeneca worth $4.13M as of Q2 2026.
  • Kayne Anderson Rudnick Investment Management bought 7,373 AstraZeneca shares in Q2 2026, an estimated $1.39M.
  • AstraZeneca made up 0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #286 holding.
  • Kayne Anderson Rudnick Investment Management first reported a position in AstraZeneca in Q3 2013 and has held it in 43 quarters since.
  • Kayne Anderson Rudnick Investment Management's AstraZeneca position peaked at $14.3M in Q4 2017.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.